Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apnimed
Biotech
Apnimed eyes FDA sleep apnea submission after positive results
AD109 met the trial's primary endpoint, reducing sleep apnea severity by a statistically significant 55.6% compared to baseline.
Darren Incorvaia
May 19, 2025 6:00am
Pfizer's migraine market chief joins Apnimed—Chutes & Ladders
Jan 26, 2024 9:30am
Two biotechs go public while Apnimed bides its time
Oct 2, 2023 11:02am
Apnimed nails study of sleep apnea med, tees up phase 3 test
May 22, 2023 10:45am
Apnimed secures $62.5M to push sleep disorder drug development
May 4, 2022 10:22am
Apnimed sees positives in new sleep apnea drug data
Oct 13, 2021 7:30am
